29 Atopic Dermatitis Clinical Trials in Scottsdale, AZ (2026)

Q: How do I join a clinical trial in Scottsdale?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Scottsdale research site will contact you.

Recruiting Atopic Dermatitis Studies in Scottsdale

NCT04373564Recruiting

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the orga...

Scottsdale, AZPHASE42,076 participantsGuerbet

View Study Details

NCT05208047Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two...

Scottsdale, AZPHASE3482 participantsCogent Biosciences, Inc.

View Study Details

NCT05541016Recruiting

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

This phase II trial examines the use of blood-based biomarkers is to help inform decision making for treatment and radiation therapy for patients with human papillomavirus (HPV) positive oropharyngeal...

Scottsdale, AZPHASE2455 participantsMayo Clinic

View Study Details

NCT05824975Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembro...

Scottsdale, AZPHASE1358 participantsGI Innovation, Inc.

View Study Details

NCT04752722Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phase...

Scottsdale, AZPHASE1350 participantsenGene, Inc.

View Study Details

NCT07567846Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a re...

Scottsdale, AZPHASE1260 participantsGenentech, Inc.

View Study Details

NCT06992427Recruiting

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous ...

Scottsdale, AZPHASE3228 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT05800665Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also ide...

Scottsdale, AZPHASE1210 participantsGenentech, Inc.

View Study Details

NCT06389136Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants w...

Scottsdale, AZPHASE3200 participantsAbbVie

View Study Details

NCT05405595Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic s...

Scottsdale, AZPHASE1186 participantsAdagene Inc

View Study Details

NCT06251310Recruiting

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with...

Scottsdale, AZPHASE1186 participantsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

View Study Details

NCT07454642Recruiting

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or m...

Scottsdale, AZPHASE1174 participantsAvacta Life Sciences Ltd

View Study Details

NCT07216027Recruiting

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this co...

Scottsdale, AZPHASE2165 participantsPfizer

View Study Details

NCT05270213Recruiting

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endo...

Scottsdale, AZPHASE1164 participantsRiboscience, LLC.

View Study Details

NCT07524348Recruiting

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors...

Scottsdale, AZPHASE1149 participantsSamsung Bioepis Co., Ltd.

View Study Details

NCT07225569Recruiting

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

This is a multinational, randomized, double-blind, placebo-controlled, Phase 2, dose finding study to evaluate the efficacy and safety of different doses of SAR445399 in adult participants with modera...

Scottsdale, AZPHASE2144 participantsSanofi

View Study Details

NCT06425926Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary ef...

Scottsdale, AZPHASE1117 participantsGeorgiamune Inc

View Study Details

NCT06249048Recruiting

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Pati...

Scottsdale, AZPHASE1108 participantsStrand Therapeutics Inc.

View Study Details

NCT07361562Recruiting

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity ...

Scottsdale, AZPHASE1100 participantsCogent Biosciences, Inc.

View Study Details

NCT06234098Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-196...

Scottsdale, AZPHASE1100 participantsAlyssum Therapeutics

View Study Details

NCT06532279Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiat...

Scottsdale, AZPHASE298 participantsNRG Oncology

View Study Details

NCT06778863Recruiting

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation....

Scottsdale, AZPHASE190 participantsClasp Therapeutics, Inc.

View Study Details

NCT07244263Recruiting

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may bec...

Scottsdale, AZPHASE290 participantsTakeda

View Study Details

NCT05552755Recruiting

Evaluate REC-4881 in Patients With FAP

This is a multicenter, two-part trial in participants with Familial Adenomatous Polyposis (FAP)....

Scottsdale, AZPHASE167 participantsRecursion Pharmaceuticals Inc.

View Study Details

NCT05329103Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced sol...

Scottsdale, AZPHASE165 participantsPeel Therapeutics Inc

View Study Details

NCT04282044Recruiting

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination w...

Scottsdale, AZPHASE160 participantsBioEclipse Therapeutics

View Study Details

NCT06959706Recruiting

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pha...

Scottsdale, AZPHASE150 participantsTagworks Pharmaceuticals BV

View Study Details

NCT06770764Recruiting

Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors

This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic s...

Scottsdale, AZPHASE150 participantsTrutino Biosciences Inc.

View Study Details

NCT07025369Recruiting

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagn...

Scottsdale, AZPHASE230 participantsMayo Clinic

View Study Details

About Atopic Dermatitis Clinical Trials in Scottsdale

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 29 atopic dermatitis clinical trials recruiting participants in Scottsdale, AZ. These studies are seeking a combined 6,812 participants. Research is being sponsored by Guerbet, Cogent Biosciences, Inc., Mayo Clinic and 23 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Scottsdale — FAQ

Are there atopic dermatitis clinical trials in Scottsdale?

Yes, there are 29 atopic dermatitis clinical trials currently recruiting in Scottsdale, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Scottsdale?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Scottsdale research site will contact you about next steps.

Are clinical trials in Scottsdale free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Scottsdale studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 29 active trials in Scottsdale are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated October 9, 2026 from ClinicalTrials.gov